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cells along two separate routes. An extra-
follicular pathway generates short-lived, 
low-affinity plasmablasts, whereas the 
follicular route gives rise to specialized 
microenvironments called germinal cen-
ters, in which affinity maturation of the 
antibody response takes place (7). Within 
germinal centers, antigen-specific B cells 
acquire random point mutations targeted 
at the Ig V region genes that change the 
specificity of the B cell receptor. Those B 
cells that consequently bind antigen with 
higher affinity are thought to gain com-
petitive advantage to receive selection sig-
nals from specialized TFH cells. Selected 
B cells terminally differentiate into long-
lived memory B cells or memory plasma 
cells that home to the bone marrow (7).
Despite the described resistance of HIV 
to antibody-mediated neutralization, 
up to 25% of HIV-1–infected individuals 
manage to develop high titers of broadly 
neutralizing antibodies over time. The 
high-affinity human antibody VRC01, 
which recognizes the initial site of CD4 
attachment on HIV-1 GP120 and neutral-
izes about 90% of HIV-1 isolates, appears 
to evolve from a low-affinity unmutated 
germline ancestor via the acquisition of 
a vast number — 70 to 90 — of somatic 
mutations (8). This represents around a 
4-fold higher frequency of changes than 
those typically observed during the affin-
ity maturation process. These and other 
data have suggested a germinal center 
origin and TFH-mediated selection of 
broadly neutralizing antibodies and raise 
the possibility that altered selection in 
germinal centers may contribute to the 
failure to generate protective antibodies 
in infected individuals.
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HIV infection leads to progressive destruction of infected CD4 T cells, 
hypergammaglobulinemia, and loss of memory B cells. Germinal centers, 
which are key to memory B cell formation and protective antibody respons-
es, are major HIV reservoirs in which the virus replicates within T follicular 
helper (TFH) cells. In this issue of the JCI, the Koup and Streeck groups 
report that chronic SIV/HIV infection promotes TFH cell accumulation, 
which may drive B cell dysregulation. Their discoveries suggest that HIV 
harnesses TFH cells to evade the antibody response.
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Antibodies play an essential role in the pro-
tection against viral infection, acting through 
different effector mechanisms to prevent viral 
entry into host cells and eliminate infected 
cells. A few viruses, however, have evolved 
sophisticated mechanisms to evade the neu-
tralizing antibody response and therefore 
persist. In the case of HIV-1, multiple mecha-
nisms enable it to evade antibody binding 
and replicate at leisure. These mechanisms 
include the death of virus-specific CD4 T cells 
that are required to help the B cell response, 
a high mutation rate that allows the rapid 
emergence of antigenic escape variants, and a 
structure of the envelope complex that makes 
conserved epitopes relatively inaccessible to 
antibodies (1, 2). In addition to preventing 
otherwise effective antibodies from inhibit-
ing virus entry into cells, HIV can also alter 
the quality of the antibody response: chronic 
HIV infection is associated with hypergam-
maglobulinemia, poor antibody responses to 
protein vaccines, and decreased antigen-spe-
cific memory B cells (reviewed in ref. 3). The 
studies in this issue of the JCI by Lindqvist 
et al. (4) and Petrovas et al. (5), together with a 
parallel study by Hong et al. (6), suggest that 
accumulation of T follicular helper (TFH) 
cells, together with possibly altered function 
during chronic HIV infection, may be at the 
root of this form of humoral evasion.
Germinal center origin of protective 
anti-HIV antibodies
B cells that receive cognate T cell help can 
differentiate into antibody-producing 
HIV infects and expands TFH cells
It has been known since the late 1980s 
that germinal centers constitute the larg-
est reservoirs of HIV virions (9), which are 
retained in the form of immune complexes 
on the processes of follicular dendritic cells 
(FDCs) (10). It has also been suggested that 
active viral infection occurs primarily at 
these sites during clinical latency (11). Viral 
replication does not occur in FDCs them-
selves, but rather in germinal center CD4 
T cells, now known as TFH cells (12–14). 
TFH susceptibility to SIV infection is also 
confirmed in the current study by Petrovas 
and colleagues (5). There have even been 
suggestions that HIV-1 may replicate more 
actively in germinal center TFH cells com-
pared with that in other CD4 T cells (15).
In the context of murine LCMV infection, 
viral persistence promotes the accumula-
tion of TFH cells in mouse secondary lym-
phoid tissues, which helps control infec-
tion (16). Now three groups also report 
TFH cell accumulation during SIV and HIV 
infection. Petrovas et al. observed that the 
proportion of TFH cells was increased by 
approximately 8 fold in 50% of chronically 
SIV-1–infected rhesus macaques (RMs) — 
designated “TFHhi” — compared with that 
in uninfected or acutely infected RMs or 
the “TFHlo” group of chronically infected 
RMs (5). Hong and colleagues enumerated 
TFH cells per unit area of lymph node sec-
tions; an approximately 4-fold increase in 
TFH cells was also observed in chronically 
infected macaques compared with that in 
uninfected or acutely infected ones (6). 
These results suggest an increase in TFH 
cells in absolute numbers, as opposed to 
a lower rate of depletion compared with 
other CD4 T cell subsets. In the study by 
Lindqvist et al., HIV-infected individuals 
had approximately 10-fold higher frequen-
cies of TFH cells compared with those of 
uninfected subjects (4). This is in itself 
quite extraordinary since HIV kills the 
vast majority of cells it infects (17), and, 
as discussed above, TFH cells themselves 
are susceptible to infection. None of the 
groups observed a correlation between 
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Figure 1
Potential mechanisms by which TFH cells drive B cell dysregulation and constitute privileged virus reservoirs in HIV infection. (i) Excessive 
IL-6 produced by FDCs that harbor HIV viruses leads to upregulation of BCL-6 and increased differentiation and/or maintenance of TFH cells. 
Increased TFH cell numbers, together with abundant antigen, lowers competition for B cell selection reducing affinity maturation. (ii) Chronic virus 
infection changes the TFH cell expression of key molecules, including BCL6, IL6RA, IL4, LIGHT, and TGIF1, leading to altered function that may 
contribute to decreased memory B cell formation. (iii) In HIV-infected individuals, a larger fraction of TFH cells secrete IL-21 and possibly other 
cytokines known to promote B cell differentiation and antibody production; this can contribute to the hypergammaglobulinemia. (iv) The high IL-6 
levels found in HIV infection may directly promote plasmacytosis and even enhance differentiation of memory B cells into plasma cells, leading 
to hypergammaglobulinemia and loss of memory B cells. (v) HIV replicates in TFH cells, and this may be enhanced by FDC-derived cytokines, 
including TNF. Exposure to high levels of IL-6 might also explain the increased proliferative rate of TFH cells in infected individuals, which may 
help maintain the viral reservoirs. (vi) It has been suggested that infection of TFH cells may be a strategy for viral persistence, since germinal 
centers are relatively devoid of cytolytic CD8+ T cells. GC, germinal center.
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the TFH cell expansion seen in chronic 
HIV infection is beneficial or detrimental 
in mounting a high-affinity, broadly neu-
tralizing antibody response against HIV in 
humans. TFH cell expansion was shown to 
help control chronic LCMV viral infection 
in mice (16) and correlate with production 
of high-affinity anti-SIV IgG antibodies in 
macaques (5). However, finding that the 
TFH cell expansion in humans favored 
accumulation of GAG-specific rather 
than envelope GP120-specific T cells (4) 
— broadly neutralizing antibodies are typi-
cally directed against structures in enve-
lope — suggests that this TFH cell response 
may not be terribly helpful in controlling 
the infection. The implications of the 
recent discoveries for understanding HIV 
latency are also potentially exciting. Ger-
minal centers store large quantities of HIV 
virus held on FDCs. The finding that TFH 
cells, which are susceptible to HIV infec-
tion, accumulate in lymph nodes rather 
than being depleted, suggests these cells 
may constitute privileged latent reservoirs 
(Figure 1, v). It has been suggested that the 
paucity of SIV-specific CD8+ T cells in fol-
licles may protect infected TFH cells from 
being killed (ref. 6 and Figure 1, vi). Con-
siderable effort is currently being directed 
toward the development of treatments that 
activate gene transcription to eliminate 
HIV latent reservoirs. It is conceivable that 
these or other antiretroviral drugs could be 
targeted to germinal center TFH cells by 
coupling them to antibodies such as PD-1. 
Finally, monitoring memory TFH-like cells 
in the blood has proven a useful biomarker 
of TFH cells and germinal center dysregu-
lation in secondary lymphoid tissues in the 
context of autoimmunity (27). Given the 
parallels with chronic HIV infection, it is 
likely that circulating TFH-like cells may 
be a useful biomarker of the size of the HIV 
chronic reservoirs and provide a rationale 
for using TFH-targeted therapies.
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with that in treated individuals (4). It is 
therefore possible that excess of this and 
other TFH-derived cytokines, such as IFN-γ 
and IL-10, contributes to hypergamma-
globulinemia (Figure 1, iii). Furthermore, 
the increased amounts of IL-6 found in 
chronic HIV infection are likely to increase 
plasma cell survival and thus augment 
total IgG levels (Figure 1, iv).
Another intriguing observation was the 
inverse correlation between the proportion 
of TFH cells and memory B cells (4). There 
are at least two different explanations for 
this effect. First, it is likely that TFH cell 
accumulation is accompanied by functional 
changes in TFH cells, and this may impair 
germinal center B cell selection and termi-
nal differentiation (Figure 1, ii). This is sug-
gested by the fact that the TFH/memory 
B cell inverse correlation was only observed 
in HIV-infected individuals but not in unin-
fected individuals (4) and by the observed 
differences in gene expression between 
TFH cells from infected and uninfected 
macaques (5). For example, the observed 
upregulation of TGIF1, which limits 
TGF-β–responsive gene expression, may act 
in a manner analogous to the depletion of 
follicular Tregs, which has been shown to 
lead to expanded germinal centers contain-
ing increased numbers of non-antigen-spe-
cific GC B cells (22). Also, downregulation 
of LIGHT, which costimulates CD40 trig-
gering (23), may dampen memory B cell for-
mation; CD40 signals have been reported to 
bias the differentiation of germinal center 
B cells toward memory rather than plasma 
cells (24). Increased expression of IL-6Ra 
and BCL-6 in TFH cells is also likely to con-
fer functional changes. The other possibil-
ity is that excessive IL-6 signals directly to 
memory B cells and promotes their termi-
nal differentiation into plasma cells (Figure 
1, iv); precedents for this action of IL-6 have 
been previously described (25). Therefore, 
it is possible that memory B cell formation 
is intact, but further differentiation into 
plasma cells causes memory B cell depletion 
(Figure 1, iv).
Perspectives
Collectively, these studies suggest that over-
activity and possibly dysregulation of TFH 
cells explains the crippling B cell defects 
associated with HIV infection. It’s also 
tempting to speculate that this TFH cell 
abnormality underpins the overrepresenta-
tion of autoimmune conditions and auto-
antibody development in HIV infection 
(26). A key outstanding issue is whether 
HIV-1 plasma viral load and TFH cell num-
bers, although it is possible that such cor-
relation might exist with tissue virus levels; 
virus is known to persist in tissues even 
when it is undetectable in the blood (18).
What drives the TFH cell accumulation 
in chronic HIV infection? First, TFH cells 
extracted from HIV-infected individuals 
expressed more BCL-6 — the transcription 
factor required for TFH formation and 
maintenance (19) — than those from treat-
ed or uninfected subjects (4) (Figure 1, i). 
In the context of chronic LCMV viral infec-
tion, TFH cell accumulation occurs as a 
consequence of IL-6 produced by a radio-
resistant cell (16), and FDCs are a plausible 
candidate for this role within germinal cen-
ters. IL-6 mediates upregulation of BCL6 on 
antigen-specific CD4 T cells (19). IL-6 has 
been reported to be increased in HIV infec-
tion (20), and levels are elevated in the plas-
ma from infected macaques (5). Consistent 
with a prominent role for IL-6 in driving 
TFH cell expansion, IL-6 receptor signal-
ing was increased in SIV-infected RMs with 
high frequency of TFH cells: IL-6Rα was 
found expressed at increased levels on TFH 
cells (Figure 1, ii). Furthermore, TFH cells 
had increased phosphorylation of STAT3, 
which mediates IL-6 receptor signaling (16).
Aberrant TFH expansion and 
function may contribute to B cell 
abnormalities
Accumulation of TFH cells has been shown 
to maintain increased numbers of germi-
nal center B cells and cause the prototypic 
systemic autoimmune disease SLE (21), 
probably due to the lowered threshold of B 
cell selection in germinal centers. Intrigu-
ingly, and as Moir and Fauci have pointed 
out, virtually the same B cell abnormalities 
have been found in HIV and SLE (3). The 
explanation for this similarity may again 
lie in the accumulation of TFH cells: the 
three studies discussed here noted that the 
increase in TFH cells in chronically infect-
ed subjects was accompanied by parallel 
increases in germinal center B cells. Also, a 
positive correlation was observed between 
total IgG and both the proportion of TFH 
cells and BCL-6 expression on these cells 
(4). TFH cell accumulation during HIV 
infection, together with excess antigen 
held on FDCs, may lower the threshold 
for B cell selection in germinal centers and 
lead to the emergence of low-affinity vari-
ants (Figure 1, i). Lindqvist et al. observed 
that a larger fraction of TFH cells secreted 
IL-21 in untreated individuals compared 
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